Reserve Antibiotics Benefits: G-BA Designates M...

By João L. Carapinha

April 18, 2025

The G-BA has completed its early benefit assessment of Meropenem/Vaborbactam (Vaborem). The authorities have designated it as a reserve antibiotic for adult patients with serious gram-negative bacterial infections where treatment alternatives are ...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.